Estimated frequency of fusions in the tropomyosin receptor kinase (TRK) gene by cancer type*

Tumor type	Frequency (%)	Fraction
Inflammatory myofibroblastic tumor	17.70	3 of 17
Salivary gland carcinoma	5.08	13 of 256
Thyroid carcinoma	2.28	13 of 571
Sarcoma	0.68	13 of 1915
Glioma/neuroepithelial tumor	0.55	8 of 1465
Appendiceal adenocarcinoma	0.48	1 of 208
Melanoma	0.36	4 of 1125
Pancreatic adenocarcinoma	0.34	5 of 1492
Colorectal carcinoma	0.31	9 of 2929
Neuroendocrine tumor	0.31	1 of 322
Cholangiocarcinoma	0.25	2 of 787
Lung adenocarcinoma	0.23	9 of 3993
Breast carcinoma	0.13	6 of 4458

* Excludes cancers highly enriched for TRK fusions (eg, congenital melanocytic nevi, infantile fibrosarcoma, mammary analogue secretory carcinoma, secretory breast carcinoma).

Adapted by permission from Macmillan Publishers Ltd: Modern Pathology. Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 2019. Copyright © 2019. https://www.nature.com/modpathol/.

Graphic 126089 Version 1.0

خرید پکیج

Estimated frequency of fusions in the tropomyosin receptor kinase (TRK) gene by cancer type*